DF/HCC Renal Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 6801547
• 负责人: Michael Benjamin Atkins
• 金额: $ 244.77万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6801547
• 关键词: clinical research; renal cell carcinoma

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence in Renal Cancer originating from the Renal Cancer Program-in-Development of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Renal Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Identification of markers for early detection and monitoring of high-risk RCC populations; 2) Inhibition of VHL-regulated growth factor pathways for treatment of RCC; 3) Combination radiofrequency ablation and antivascular/anitangiogenesis therapy for RCC; 4) Identification of molecular and immunologic correlates of RCC prognosis and responsiveness to therapy, and 5) Dendritic cell/tumor fusions in conjunction with IL-12 as novel immunotherapy for RCC. These projects are integrated by four cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; 3) Tissue Acquisition, Pathology and Clinical Data, and 4) Monitoring. This SPORE application outlines a Developmental Projects Program which includes a plan for selection and review of projects, and eight sample projects that could be considered for support. We also include a Career Development Award Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Renal Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with renal cancer.

描述（由申请人提供）：本申请代表了肾癌卓越研究专门计划的创建，该计划源自新配置的丹纳法伯哈佛癌症中心 (DF/HCC) 和贝斯医院的肾癌计划开发项目以色列女执事医疗中心。 DF/HCC 肾癌 SPORE 包括来自所有哈佛附属医院的研究人员 - 贝斯以色列女执事医疗中心、达纳法伯癌症研究所、麻省总医院、布莱根妇女医院和儿童医院医疗中心，以及如哈佛大学公共卫生学院。 该应用程序支持五个主要项目，包括： 1) 鉴定用于早期检测和监测高危 RCC 人群的标记物； 2) 抑制VHL调节的生长因子通路来治疗肾细胞癌； 3) 射频消融与抗血管/抗血管生成联合治疗肾细胞癌； 4) 鉴定 RCC 预后和治疗反应的分子和免疫学相关性，以及 5) 树突状细胞/肿瘤融合与 IL-12 联合作为 RCC 的新型免疫疗法。 这些项目由四个核心集成。它们是： 1) 管理、评估和规划； 2）生物统计学； 3) 组织采集、病理学和临床数据，以及 4) 监测。 此 SPORE 申请概述了一个开发项目计划，其中包括项目选择和审查的计划，以及可以考虑支持的八个示例项目。 我们还包括一项职业发展奖励计划，该计划概述了识别、支持和审查肾癌领域有才华的年轻研究人员的机制。 DF/HCC 肾癌 SPORE 的总体目标是将生物学和技术进步转化为对肾癌患者具有临床意义的进步。